GENE THERAPY company Oxford BioMedica is seeking partners to develop two of its potential treatments after half-year losses rose to £3.6m.
It has cash of £16.3m, enough to last until the first quarter of 2012. By then it hopes to have completed clinical trials of eye disease and cancer treatments.
It is also talking to potential partners to prepare its Parkinson's disease treatment, ProSavin, for clinical trials next year and to expand its TroVAX vaccine for renal, ovarian and other cancers.
Chief executive officer John Dawson said: “We have made good progress across our lead development programmes during the first half of 2010.
"The long-term safety profile and sustained benefit of ProSavin is extremely promising and the new administration method has the potential to add significant value to this programme.
"With our partner Sanofi-Aventis, we remain focused on advancing all four ocular programmes into clinical development during the next twelve months and also look forward to the development of TroVax.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article